Brigitte (Bigs) Robertson, MD

Chief Medical Officer

Dr. Robertson joins Delix from Yumanity Therapeutics, where she served as Chief Medical Officer since 2019. Her industry career started as a physician scientist in translational medicine at GlaxoSmithKline in the Center for Excellence in Drug Discovery. She then joined Sunovion Pharmaceuticals, where she held senior roles in clinical development and experimental medicine. Dr. Robertson subsequently spent more than eight years at Takeda (formerly Shire), and served as the Therapeutic Area Head of Neuroscience, where she led global clinical development and helped drive the disease area strategy for a large portfolio of early and late-stage assets in neurological, psychiatric, and neurodegenerative disorders. In that role she successfully guided multiple programs through global regulatory review and gained approval across several indications. Dr. Robertson has authored numerous articles published in leading peer-reviewed journals, while also taking part in several industry and academic consortia to advance biomarkers and improve trial outcomes in CNS drug development.

Dr. Robertson earned her medical degree from the University of Health Sciences Georgia before completing residency training with a focus on neuropsychiatry at the University of Colorado Health Sciences Center. She completed a fellowship in child psychiatry and a second post-doctoral research fellowship, sponsored by the NIH in neuroimaging and psychopharmacology at the University of California in San Diego (UCSD). In addition, she has held faculty positions at CCP Children's hospital in San Diego, USCD, and Duke University.